{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:59:30Z","timestamp":1794441570232,"version":"4.9.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["214844"],"award-info":[{"award-number":["214844"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.biopha.2026.119097","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:58:16Z","timestamp":1770908296000},"page":"119097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Placental transfer characteristics and functional impact of SGLT2 inhibitors in human experimental models"],"prefix":"10.1016","volume":"196","author":[{"given":"Sabrina","family":"Kuoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dolder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1617-6524","authenticated-orcid":false,"given":"Regula","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7691-965X","authenticated-orcid":false,"given":"Nicole","family":"Ochsenbein-K\u00f6lble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4489-0952","authenticated-orcid":false,"given":"Ana Paula","family":"Sim\u00f5es-W\u00fcst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119097_bib1","series-title":"Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors","author":"Padda","year":"2025"},{"issue":"16","key":"10.1016\/j.biopha.2026.119097_bib2","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3390\/ijerph16162965","article-title":"SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects","volume":"16","author":"Tentolouris","year":"2019","journal-title":"Int J. Environ. Res Public Health"},{"issue":"12","key":"10.1016\/j.biopha.2026.119097_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.008381","article-title":"Patterns of prescribing sodium-glucose Cotransporter-2 inhibitors for medicare beneficiaries in the United States","volume":"14","author":"Sangha","year":"2021","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"issue":"9","key":"10.1016\/j.biopha.2026.119097_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023811","article-title":"National trends in use of sodium-glucose Cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015\u20132020","volume":"11","author":"Adhikari","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.biopha.2026.119097_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0322787","article-title":"Assessing the global burden of Type 2 diabetes in women of reproductive age","volume":"20","author":"Luo","year":"2025","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2026.119097_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12020-025-04337-1","article-title":"Global, regional, and national burden and trends of Type 2 diabetes mellitus among women of childbearing age from 1990 to 2021, with projections to 2030: a systematic analysis for the Global Burden of Disease Study 2021","volume":"90","author":"Kong","year":"2025","journal-title":"Endocrine"},{"issue":"ersetzt 33","key":"10.1016\/j.biopha.2026.119097_bib7","article-title":"Pr\u00e4konzeptionsberatung \u2013 \u201cPreconception Care\u201d","volume":"92","author":"Krischer","year":"2025","journal-title":"Expert. No"},{"issue":"2","key":"10.1016\/j.biopha.2026.119097_bib8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy","volume":"184","author":"Cesta","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.biopha.2026.119097_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1215356","article-title":"Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence","volume":"14","author":"Muller","year":"2023","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"5","key":"10.1016\/j.biopha.2026.119097_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.867","article-title":"Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions","volume":"9","author":"Matharu","year":"2021","journal-title":"Pharm. Res Perspect."},{"key":"10.1016\/j.biopha.2026.119097_bib11","author":"Sharp","year":"2023","journal-title":"Steglatro Prod. Inf."},{"issue":"01","key":"10.1016\/j.biopha.2026.119097_bib12","volume":"16","author":"Ingelheim","year":"2023","journal-title":"Jardiance Prod. Inf."},{"key":"10.1016\/j.biopha.2026.119097_bib13","first-page":"01","volume":"16","author":"AstraZeneca","year":"2023","journal-title":"Forxiga Prod. Inf."},{"key":"10.1016\/j.biopha.2026.119097_bib14","first-page":"01","article-title":"Janssen-Cilag","volume":"16","year":"2023","journal-title":"Invokana Prod. Inf."},{"key":"10.1016\/j.biopha.2026.119097_bib15","first-page":"84","article-title":"Placental structure, function and drug transfer","volume":"15","author":"Griffiths","year":"2014","journal-title":"Contin. Educ. Anaesth. Crit. Care Pain."},{"key":"10.1016\/j.biopha.2026.119097_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.addr.2016.08.002","article-title":"Placental control of drug delivery","volume":"116","author":"Al-Enazy","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.biopha.2026.119097_bib17","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2337\/dbi18-0006","article-title":"Sodium-glucose Cotransporter 2 inhibitors: a case study in translational research","volume":"68","author":"Beitelshees","year":"2019","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.biopha.2026.119097_bib18","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202301230R","article-title":"Glycolysis: a fork in the path of normal and pathological pregnancy","volume":"37","author":"Gou","year":"2023","journal-title":"Faseb J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119097_bib19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.rbmo.2015.10.005","article-title":"The endocrine function of human placenta: an overview","volume":"32","author":"Costa","year":"2016","journal-title":"Reprod. Biomed. Online"},{"key":"10.1016\/j.biopha.2026.119097_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116177","article-title":"Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: an ex vivo human placenta perfusion and in vitro study","volume":"171","author":"Kuoni","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2026.119097_bib21","doi-asserted-by":"crossref","DOI":"10.1289\/EHP4860","article-title":"Transfer and metabolism of the xenoestrogen zearalenone in human perfused placenta","volume":"127","author":"Warth","year":"2019","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.biopha.2026.119097_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123841","article-title":"Simultaneous LC-MS\/MS quantification of SGLT2 inhibitors and antipyrine in medium and tissue from human ex vivo placenta perfusions","volume":"1228","author":"Kuoni","year":"2023","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"8","key":"10.1016\/j.biopha.2026.119097_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220323","article-title":"Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model","volume":"14","author":"Mandelbrot","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2026.119097_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8020012","article-title":"Evaluation of P-glycoprotein inhibitory potential using a rhodamine 123 accumulation assay","volume":"8","author":"Jouan","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119097_bib25","article-title":"Dulaglutide and pregnancy: a comprehensive safety assessment using the ex vivo placenta perfusion and in vitro models","volume":"16","author":"Kuoni","year":"2025","journal-title":"Front. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2026.119097_bib26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.placenta.2003.12.001","article-title":"An analysis using DNA microarray of the time course of gene expression during syncytialization of a human placental cell line (BeWo)","volume":"25","author":"Kudo","year":"2004","journal-title":"Placenta"},{"issue":"12","key":"10.1016\/j.biopha.2026.119097_bib27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/molehr\/gaz061","article-title":"Transcriptomic profiling of trophoblast fusion using BeWo and JEG-3 cell lines","volume":"25","author":"Msheik","year":"2019","journal-title":"Mol. Hum. Reprod."},{"issue":"1","key":"10.1016\/j.biopha.2026.119097_bib28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/biomedicines11010143","article-title":"The molecular pharmacology of phloretin: anti-inflammatory mechanisms of action","volume":"11","author":"Habtemariam","year":"2023","journal-title":"Biomedicines"},{"issue":"1(1","key":"10.1016\/j.biopha.2026.119097_bib29","article-title":"Drug transporters expressed in the human placenta and models for studying maternal-fetal drug transfer","volume":"59","author":"Dallmann","year":"2019","journal-title":"J. Clin. Pharm."},{"issue":"9","key":"10.1016\/j.biopha.2026.119097_bib30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1124\/dmd.120.000067","article-title":"Gestational age-dependent abundance of human placental transporters as determined by quantitative targeted proteomics","volume":"48","author":"Anoshchenko","year":"2020","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.biopha.2026.119097_bib31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1471-0528.1993.tb15315.x","article-title":"The intravascular mass of albumin during human pregnancy: a serial study in normal and diabetic women","volume":"100","author":"Whittaker","year":"1993","journal-title":"Br. J. Obstet. Gynaecol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119097_bib32","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/AOG.0b013e3181c2bde8","article-title":"Pregnancy and laboratory studies: a reference table for clinicians","volume":"114","author":"Abbassi-Ghanavati","year":"2009","journal-title":"Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119097_bib33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1515\/jbcpp-2021-0312","article-title":"An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics","volume":"33","author":"Eke","year":"2022","journal-title":"J. Basic Clin. Physiol. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119097_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/clpt.2011.66","article-title":"The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs","volume":"90","author":"Hutson","year":"2011","journal-title":"Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119097_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.59249\/JTIV4138","article-title":"Natural physiological changes during pregnancy","volume":"97","author":"Chandra","year":"2024","journal-title":"Yale J. Biol. Med"},{"key":"10.1016\/j.biopha.2026.119097_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.837694","article-title":"Gestational age variation in human placental drug transporters","volume":"13","author":"Goetzl","year":"2022","journal-title":"Front. Pharm."},{"issue":"32","key":"10.1016\/j.biopha.2026.119097_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202301428","article-title":"Modeling the progression of placental transport from early- to late-stage pregnancy by tuning trophoblast differentiation and vascularization","volume":"12","author":"Kouthouridis","year":"2023","journal-title":"Adv. Health Mater."},{"key":"10.1016\/j.biopha.2026.119097_bib38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.placenta.2018.10.008","article-title":"Comparative expression patterns of selected membrane transporters in differentiated BeWo and human primary trophoblast cells","volume":"72-73","author":"Kallol","year":"2018","journal-title":"Placenta"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226001290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226001290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:41:16Z","timestamp":1781880076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226001290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"alternative-id":["S0753332226001290"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119097","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Placental transfer characteristics and functional impact of SGLT2 inhibitors in human experimental models","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119097"}}